Incyte stock reports 38 percent revenue growth as shares trade at USD 123.47

{
  "signal_id": "65e7a71c-cd8a-d7ce-8431-2c245036338d",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-09-25T13:59:47+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/incyte-stock-reports-38-percent-revenue-growth-as-shares-trade-at-usd/70184140",
    "title": "Incyte stock reports 38 percent revenue growth as shares trade at USD 123.47 - AD HOC NEWS",
    "excerpt": "Incyte (ISIN US45337C1027) stock reports 38 percent revenue growth as shares trade at USD 123.47 on Nasdaq on September 25, 2026 at 9:57 a.m. ET. The latest commercial development is an expanded Opzelura partnership for Australia announced on September 20, 2026. According to Yahoo Finance , Incyte generated USD 1.67 billion in Q2 2026 revenue, up 38 percent from the year-ago quarter and above the USD 1.46 billion consensus estimate. The same Q2 2026 report showed adjusted earnings per share of USD 3.09 versus USD 2.00 consensus. Opzelura sales reached USD 449.7 million, up 173 percent year over year, although the result included a USD 246 million non-cash benefit from reversed accruals. PR Newswire reported on September 20, 2026 that Specialised Therapeutics expanded its existing partnership with Incyte to commercialize, register and distribute ruxolitinib cream in Australia. Incyte will continue development and manufacturing, while Specialised Therapeutics handles regulatory submissions, medical affairs, marketing and distribution. The release also said more than one million patients globally had been treated with Opzelura. Incyte stock was trading at USD 123.47 on Nasdaq at 9:57 a.m. ET on September 25, 2026, down USD 0.97 or 0.78 percent from the prior close of USD 124.44. The session range was USD 123.09 to USD 125.99, and market capitalization stood at USD 25,026,077,210...",
    "summary": "Incyte reported Q2 2026 revenue of USD 1.67 billion, a 38% increase year-over-year.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2706323_1920_1080.webp",
    "confidence": 0.9,
    "published_at": "2026-09-25T13:59:47Z",
    "article_sentence": "According to Yahoo Finance , Incyte generated USD 1.67 billion in Q2 2026 revenue, up 38 percent from the year-ago quarter and above the USD 1.46 billion consensus estimate.",
    "amount_normalized": 1670000000
  }
}

curl https://signals.autobound.ai/v1/signals/65e7a71c-cd8a-d7ce-8431-2c245036338d \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"incyte.com","limit":20}'